Shiloh
Editor, Senior Moderator
Source: https://www.science.org/doi/10.1126/science.abm0620
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, Nickilou Y. Krigbaum, and Arthur W. Wallace
Science • 4 Nov 2021 • First Release •
DOI: 10.1126/science.abm0620
Abstract
We report SARS-CoV-2 vaccine effectiveness against infection (VE-I) and death (VE-D) by vaccine type (n = 780,225) in the Veterans Health Administration, covering 2.7% of the U.S. population. From February to October 2021, VE-I declined from 87.9% to 48.1%, and the decline was greatest for the Janssen vaccine resulting in a VE-I of 13.1%. Although breakthrough infection increased risk of death, vaccination remained protective against death in persons who became infected during the Delta surge. From July to October 2021, VE-D for age 65 years was 73.0% for Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTech; VE-D for age ≥65 years was 52.2% for Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTech. Findings support continued efforts to increase vaccination, booster campaigns, and multiple, additional layers of protection against infection....
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, Nickilou Y. Krigbaum, and Arthur W. Wallace
Science • 4 Nov 2021 • First Release •
DOI: 10.1126/science.abm0620
Abstract
We report SARS-CoV-2 vaccine effectiveness against infection (VE-I) and death (VE-D) by vaccine type (n = 780,225) in the Veterans Health Administration, covering 2.7% of the U.S. population. From February to October 2021, VE-I declined from 87.9% to 48.1%, and the decline was greatest for the Janssen vaccine resulting in a VE-I of 13.1%. Although breakthrough infection increased risk of death, vaccination remained protective against death in persons who became infected during the Delta surge. From July to October 2021, VE-D for age 65 years was 73.0% for Janssen, 81.5% for Moderna, and 84.3% for Pfizer-BioNTech; VE-D for age ≥65 years was 52.2% for Janssen, 75.5% for Moderna, and 70.1% for Pfizer-BioNTech. Findings support continued efforts to increase vaccination, booster campaigns, and multiple, additional layers of protection against infection....